HRS-9821 Inhalation Suspension for COPD: Safety and Dose Finding in Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial will compare HRS-9821 inhalation suspension to a placebo in adults with COPD. Eligible participants are adults aged 40 to under 80 with FEV1/FVC less than 0.7 and FEV1 between 30% and 80%, who have a stable COPD regimen for at least 4 weeks prior to screening. The study will assess safety and efficacy of different doses of HRS-9821 and identify a dose with acceptable tolerability. Participants will be randomized to receive either the active inhalation suspension or placebo and will undergo periodic assessments of lung function and related outcomes. The trial is sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd and conducted at Shanghai Tongji Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 40 years old and \< 80 years old, male or female.
2. Meet the weight standard.
3. Smoking history ≥ 10 pack-years.
4. COPD has been diagnosed ≥ 1 year.
5. 4 weeks before screening, the background treatment for COPD was stable.
6. FEV1/FVC \< 0.7, 30% ≤ FEV1 ≤ 80%.
7. mMRC score ≥ 2.
8. The inspection and medication can be completed as required.
9. Non-pregnant and breastfeeding state.
10. Able and willing to provide a written informed consent.

Exclusion Criteria:

1. History of life-threatening COPD.
2. Other pulmonary diseases that may affect the efficacy evaluation of this study.
3. Concurrent diseases other than COPD that may affect lung function.
4. History of asthma.
5. Pulmonary heart disease requiring clinical intervention, or moderate to severe pulmonary hypertension.
6. Malignant tumors within 5 years.
7. Uncontrolled severe cardiovascular and cerebrovascular diseases within 1 year.
8. Unstable diseases.
9. Acute exacerbation of COPD within 12 weeks, hospitalization for COPD or pneumonia within 6 months.
10. Infection in the lungs or other parts occurs within 16 weeks and requires treatment.
11. Immunosuppression.
12. Uncontrolled hypertension.
13. Lung resection, surgical lung volume reduction or endoscopic treatment for COPD.
14. Undergone major surgery or planned surgery within 14 months.
15. Abnormal chest images have clinical significance.
16. Tuberculosis infection requiring treatment within 16 to 12 months.
17. Virological test result was positive.
18. Laboratory blood tests and electrocardiograms were significantly abnormal.
19. Requires oxygen inhalation or intermittent oxygen inhalation therapy.
20. Hypercapnia, using or requiring long-term use of any non-invasive positive pressure ventilation device.
21. Biological agents that may have therapeutic effects on the studied disease have been used within 12 weeks or within 5 half-lives of the drug.
22. Vaccination, theophylline or drugs within 4 weeks.
23. Having participated in other clinical studies within 4 weeks and used research drugs or medical devices containing active ingredients, or still within 5 half-lives of the research drug.
24. Systemic glucocorticoids, immunosuppressants, and oral Roflumilast within 12 weeks.
25. Undergoing or planning rehabilitation treatment for pulmonary rehabilitation.
26. Non-selective β blockers within 1 week.
27. Overly potent/moderately potent drugs that inhibit or induce the liver drug-metabolizing enzyme CYP3A4 within 14 days.
28. Allergic to the research drug or salbutamol or excipients.
29. Has been used HRS-9821.
30. Drug abuse and alcohol abuse within 1 year.
31. Pregnant or lactating period or planning to be pregnant or lactating.
32. The researchers judged that there were other unsuitable circumstances.

Where it's running

• Shanghai Tongji Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Si Chen, M.M
• Email: si.chen.sc96@hengrui.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AERO-007: a inhaled LABA+LAMA combination for COPD through a nebulizer

  This study tests whether a nebulized LABA+LAMA combination can improve lung function in adults with COPD.

  Recruiting Phase 2 AeroRx Therapeutics Inc. · London and 1 other locations · NCT07896252

• Cognitive load and inhaler technique in COPD

  This study tests whether adding a short memory task while using an inhaler makes COPD patients more likely to misuse their inhaler.

  Recruiting Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie Dr. Victor Babeș Timișoara · Timișoara, Timiș County · NCT07786220

• Balance training after pulmonary rehab for COPD to help steadiness and reduce falls

  A COPD-focused balance training program called Sport4Steadiness is being tested to see if people with COPD will accept it and if the study processes work well.

  Recruiting at 3 sites Teesside University · Middlesbrough and 2 other locations · NCT07750821

• Continuous vs High-Intensity Interval Exercise in COPD

  This study tests whether continuous versus high-intensity interval exercise affects cerebral oxygenation in people with COPD.

  Recruiting George Papanicolaou Hospital · Thessaloniki, Exohi · NCT07707271

• Biomarker clues for COPD, IPF, and lung cancer

  This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.

  Recruiting Fondazione Don Carlo Gnocchi ETS · Milan, Milan · NCT07707245

• Relaxation techniques for anxiety and sleep in COPD patients

  This study tests whether Laura Mitchell’s relaxation technique or Benson’s relaxation response can help reduce anxiety, improve sleep, and lessen fatigue in adults with COPD.

  Recruiting Riphah International University · Lahore, Punjab Province · NCT07635446

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.